Quince Therapeutics Inc
NASDAQ:QNCX
Balance Sheet
Balance Sheet Decomposition
Quince Therapeutics Inc
Quince Therapeutics Inc
Balance Sheet
Quince Therapeutics Inc
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
7
|
23
|
50
|
52
|
56
|
15
|
6
|
6
|
|
| Cash |
7
|
11
|
4
|
36
|
40
|
4
|
2
|
3
|
|
| Cash Equivalents |
0
|
12
|
46
|
16
|
16
|
11
|
4
|
4
|
|
| Short-Term Investments |
0
|
49
|
50
|
82
|
51
|
75
|
69
|
35
|
|
| Other Current Assets |
0
|
1
|
6
|
4
|
5
|
4
|
2
|
3
|
|
| Total Current Assets |
8
|
73
|
106
|
138
|
112
|
94
|
77
|
44
|
|
| PP&E Net |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
6
|
64
|
60
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
18
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
|
| Long-Term Investments |
0
|
0
|
17
|
51
|
20
|
4
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
8
|
4
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
18
|
0
|
|
| Total Assets |
8
N/A
|
73
+847%
|
124
+71%
|
190
+52%
|
133
-30%
|
104
-22%
|
168
+62%
|
114
-32%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
1
|
3
|
4
|
5
|
1
|
2
|
3
|
|
| Accrued Liabilities |
1
|
1
|
6
|
13
|
9
|
2
|
3
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
|
| Total Current Liabilities |
2
|
2
|
9
|
17
|
14
|
3
|
10
|
7
|
|
| Long-Term Debt |
7
|
0
|
0
|
0
|
0
|
0
|
13
|
14
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
|
| Other Liabilities |
2
|
0
|
0
|
0
|
0
|
0
|
55
|
58
|
|
| Total Liabilities |
11
N/A
|
2
-86%
|
9
+493%
|
17
+93%
|
15
-15%
|
3
-77%
|
83
+2 410%
|
84
+2%
|
|
| Equity | |||||||||
| Common Stock |
17
|
104
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
20
|
33
|
70
|
147
|
237
|
288
|
320
|
376
|
|
| Additional Paid In Capital |
0
|
0
|
185
|
319
|
355
|
389
|
402
|
407
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
|
| Total Equity |
3
N/A
|
71
N/A
|
116
+62%
|
172
+49%
|
119
-31%
|
101
-15%
|
85
-15%
|
30
-65%
|
|
| Total Liabilities & Equity |
8
N/A
|
73
+847%
|
124
+71%
|
190
+52%
|
133
-30%
|
104
-22%
|
168
+62%
|
114
-32%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
26
|
26
|
27
|
30
|
30
|
36
|
43
|
44
|
|